Abatacept

• A Randomized Double-Blind, Placebo Controlled Trial of Abatacept (CTLA4-Ig) in Giant Cell Arteritis (ABAGART) Pending
  2024-515287-31-00 Phase III 2 countries Trustees Of The University Of Pennsylvania
• A multicenter, randomized, open-label, blinded-assessor, phase 4 study in patients with early rheumatoid arthritis to compare active convent… Pending
  2024-516723-14-00 Phase IV 4 countries Karolinska Institutet
• Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis (SMART-JIA) Pending
  2025-520923-25-00 Phase III 3 countries Duke Clinical Research Institute
• The OASE study Pending
  2026-525221-21-01 Phase IV 1 country Aalborg University Hospital
• Toward personalized medicine to guide drug withdrawal in children with juvenile idiopathic arthritis in clinical remission: a randomized cli… Recruiting
  2024-514732-24-00 Phase IV 7 countries IRCCS Istituto Giannina Gaslini
• 3TR-PARTNER-RA Recruiting
  2024-511470-79-00 Phase IV 5 countries Queen Mary University Of London
• Reduction of plasma cells as an approach to reset autoimmunity in rheumatoid arthritis Recruiting
  2024-511536-27-00 Phase I/II 1 country Charite Universitaetsmedizin Berlin KöR
• Abatacept for therapy of IgG4-related disease Recruiting
  2024-512863-30-00 Phase II 1 country Ospedale San Raffaele S.r.l.
• Efficacy of a sequential treatment strategy in Rheumatoid Arthritis. Recruiting
  2022-500234-29-00 Phase III 1 country Centre Hospitalier Universitaire De Montpellier
• An unblinded clinical Trial with random assignment to Treatment Groups in adult patients with psoriatic arthrits to evaluate how far immunos… Recruiting
  2023-508251-39-00 Phase III 2 countries Universitaetsklinikum Erlangen AöR
• RANDOMIZED CONTROLLED CLINICAL TRIAL EVALUATING METHOTREXATE OR LEFLUNOMIDE + TARGETED THERAPY VERSUS METHOTREXATE OR LEFLUNOMIDE + SULFASAL… Recruiting
  2024-516704-41-00 Phase III/IV 1 country Les Hopitaux Universitaires De Strasbourg
• Efficacy of Abatacept vs Adalimumab in Early, Autoantibody positive Rheumatoid Arthritis (RA) and who did not respond well to methotrexate. Ended
  2023-506450-20-00 Phase III 6 countries Bristol-Myers Squibb Services Unlimited Company
• A randomised, double-blind, multicentre study comparing the efficacy, safety and immunogenicity of proposed Abatacept biosimilar (DRL_AB) wi… Ended
  2023-506664-14-00 Phase III 8 countries Dr Reddy's Laboratories Limited
• A Multicenter, Adaptive, Randomized, Controlled Trial Platform to Evaluate Safety and Efficacy of Strategies and Treatments for Hospitalized… Ended
  2023-504487-41-00 Phase III 9 countries University Of Minnesota
• ABATACEPT VERSUS TOCILIZUMAB BY SUBCUTANEOUS ADMINISTRATION FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN TARGETED TREATMENT INADEQUATE RESPO… Ended
  2024-515600-39-00 Phase IV 1 country Groupement Des Hopitaux De L'Institut Catholique De Lille

Showing 1–15 of 15 trials